-
Lancet Oncol: Efficacy of pembrolizumab in classic or endemic Kaposi's sarcoma
Time of Update: 2022-04-22
The aim of this study was to evaluate the therapeutic activity of pembrolizumab in classical and endemic Kaposi's sarcoma requiring systemic therapy .
PD-1 blockade with prebrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.
-
Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer
Time of Update: 2022-04-22
Recently, a team from the Fifth Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the safety and efficacy of nivolumab (nivolumab) combined with recombinant human endostatin in previously treated advanced non-small cell lung cancer (NSCLC) .
-
JITC: Huazhong University of Science and Technology team found a new way to enhance immunotherapy!
Time of Update: 2022-04-22
A recent study by Xu Shuangbing and Wu Gang's team from the Tumor Center of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology showed that in the treatment of lung cancer, inhibition of lysine-specific demethylase 4C ( KDM4C ) can promote CXCL10 gene transcription, Enhances antitumor immunity mediated by CD8+ T cells .
-
J Clin Oncol: Efficacy of temozolomide in combination with low-dose ipilimumab and nivolumab in MSS and MGMT-deficient metastatic colorectal cancer (mCRC)
Time of Update: 2022-04-22
The primary endpoint was the 8-month progression-free survival (PFS) rate (calculated from the second part of treatment) .
The primary endpoint was the 8-month progression-free survival (PFS) rate (calculated from the second part of treatment) .
-
Br J Dermatol: Do we need to reconsider the diagnosis of melanoma in situ and severely dysplastic nevi?
Time of Update: 2022-04-22
The first is the evidence on the natural history of these lesions, which we found to be rare, as melanoma in situ and severe dysplastic nevi are usually excised .
This provides evidence for a lowering of the diagnostic threshold and expansion of disease definitions for melanoma in situ and severe dysplastic nevi .
-
JAMA Dermatol: Does Spironolactone Really Cause Increased Cancer Risk?
Time of Update: 2022-04-22
Given this official warning and uncertainty about the potential link between spironolactone use and cancer, the aim of this study was to conduct a systematic review and meta-analysis to synthesize the evidence on cancer risk from spironolactone use .
-
JNCC: Hejie academician team released the latest cancer incidence and mortality data in China
Time of Update: 2022-04-22
The mortality rates of colorectal cancer, breast cancer, thyroid cancer, prostate cancer and other tumors with high incidence in developed countries show a continuous upward trend .
-
Clin Cancer Res: Efficacy of temozolomide combined with radiotherapy vs radiotherapy alone in IDH wild-type glioblastoma
Time of Update: 2022-04-22
Does adjuvant radiotherapy combined with temozolomide improve outcomes in patients with anaplastic astrocytoma without IDH1/2 mutations with molecular features of glioblastomaThe CATNON trial was a randomized phase 3 study to investigate the effect of adjunctive or concurrent use of temozolomide during radiotherapy in patients with anaplastic astrocytoma .
-
Ther Adv Med Oncol: Peking Union Medical College Hospital team explores the best first-line treatment for HER2-altered advanced NSCLC patients in real world
Time of Update: 2022-04-22
immune blood vesselsA total of 293 patients were screened and 37 distinct HER2 mutations were identified, with the most common variant subtype being exon 20 insertions (ex20ins, n=246, 83.
-
Oncologist: Patients with locally advanced rectal cancer (LARC) treated with complete neoadjuvant therapy (TNT) did not improve prognosis
Time of Update: 2022-04-22
Therefore, a team from the United States conducted a retrospective study to evaluate the efficacy and prognosis of TNT + surgery versus neoadjuvant chemoradiotherapy + surgery + adjuvant chemotherapy in patients with locally advanced rectal cancer (LARC) .
-
J Clin Oncol: Clinical efficacy of nivolumab-tailored therapy in patients with advanced urothelial carcinoma
Time of Update: 2022-04-22
The study's tailored nivolumab therapy demonstrated significant clinical activity, supporting the use of dual checkpoint inhibitors as first-line therapy in patients with metastatic urothelial carcinoma .
The study's tailored nivolumab therapy demonstrated significant clinical activity, supporting dual-checkpoint inhibitor therapy in first-line treatment of patients with metastatic urothelial carcinoma .
-
Oncologist: Global multicenter real-world exploration of the efficacy of EGFR-TKIs in patients with rare EGFR-mutant NSCLC
Time of Update: 2022-04-22
To evaluate the efficacy of erlotinib, gefitinib, afatinib, or osimertinib as first- or second-line therapy in patients with NSCLC with rare EGFR mutations .
For patients who received EGFR TKIs as first-line therapy, the median TTF was 10.
-
J Clin Oncol: Olaparib ± cediranib vs chemotherapy in recurrent platinum-sensitive ovarian cancer
Time of Update: 2022-04-22
The patients were randomized (1:1:1) into three groups to receive platinum-based chemotherapy, olaparib, and olaparib/cediranib, respectively .
In short, the olaparib/cediranib combination did not prolong progression-free survival in ovarian cancer patients compared with chemotherapy .
-
Clin Cancer Res: Phase III clinical study CATNON showed that in IDH wild-type glioblastoma, the addition of temozolomide to radiotherapy did not improve patient outcomes
Time of Update: 2022-04-22
Recently, the journal CLINICAL CANCER RESEARCH published the results of a post-hoc analysis of a phase III clinical study CATNON (NCT00626990), which mainly evaluated whether the addition of temozolomide to radiotherapy in IDH wild-type glioblastoma improved patients.
-
Selective estrogen receptor degrader (SERD) amcenestrant in breast cancer fails to meet primary endpoint
Time of Update: 2022-04-22
The AMERA-3 trial evaluated the efficacy of oral amcenestrant as monotherapy versus physician-chosen endocrine therapy in patients with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2-negative breast cancer that progressed during or after hormone therapy .
com/story/5524831 https://firstwordpharma.
com/story/5524831 https://firstwordpharma.
-
Transl Lung Cancer Res: Association of Baseline Tumor Size (BTS) with Outcomes in NSCLC Patients Receiving Immune Monotherapy or Combination Chemotherapy
Time of Update: 2022-04-22
Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono) .
Baseline tumor size (BTS) is a prognostic factor in non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitor monotherapy (ICI-mono) .
-
Am Clin Nutrition: Meat consumption not associated with stomach cancer risk
Time of Update: 2022-04-22
Therefore, this study aimed to investigate the association between meat consumption and gastric cancer risk in Japanese men and women .
This study confirmed that meat consumption was not associated with the total number of gastric cancers in Japanese adults in a large prospective cohort study .
-
This cancer 'prefers' young people
Time of Update: 2022-04-22
Although thyroid cancer has a horribly high incidence, it has been dubbed the " most mild " cancer , given the good postoperative outcomes and high survival rates .
Look in the mirror and tilt your head back slightly, exposing your neck .
-
Chin J Cancer Res: Phase III study by Prof. Baohui Han's team shows that QL1101 and bevacizumab are equally effective in the treatment of non-squamous non-small cell lung cancer
Time of Update: 2022-04-22
Recently, the Chinese Journal of Cancer Research published a 2-year follow-up update of a study by Professor Han Baohui's team from Shanghai Chest Hospital, which mainly evaluated the comparison of bevacizumab biosimilar QL1101 with bevacizumab in the treatment of non-patients.
-
European Radiology: Evaluation of left atrial remodeling in patients with breast cancer treated with adjuvant trastuzumab by CMRI
Time of Update: 2022-04-15
In this prospective cohort study of trastuzumab-treated breast cancer patients, there was a small but significant subclinical decrease in LAEF and a modest increase in LAmin after initiation of treatment , which returned to baseline 6 months after treatment was discontinued .
